Prevail Therapeutics
Clinical trials sponsored by Prevail Therapeutics, explained in plain language.
-
Spinal injection trial seeks to slow Parkinson's progression
Disease control Recruiting nowThis early-stage study is testing the safety and behavior of a new drug, LY3962681, delivered by injection into the spinal fluid. It involves healthy volunteers receiving a single dose and Parkinson's disease patients receiving two doses. The main goal is to see how well the drug…
Phase: PHASE1 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
One-Shot gene therapy trial offers hope for gaucher disease patients
Disease control Recruiting nowThis early-stage study is testing a single intravenous dose of an experimental gene therapy called LY3884961 in adults with Gaucher disease. The main goal is to see if the treatment is safe and tolerable, while also checking if it can improve key disease measures like spleen size…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC